[at noodls] – – Independent Committee Concludes Progression-Free Survival Data From PICASSO 3 Trial Projected in First Quarter of 2013 – – Company to Host Update Call at 5:00 PM EST Today – NEW YORK, Nov. 14, 2012 (GLOBE … moreView todays social media effects on ZIOPView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingOncology-focused Celsion Corp. (NASDAQ:CLSN) announced Friday morning that the Phase III HEAT trial met its unblinding milestone, and top-line data will be released in January of 2013, sending … moreView todays social media effects on ZIOPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – NEW YORK, Nov. 7, 2012 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today … moreView todays social media effects on ZIOPView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By David SobekWhile investors have been focusing their attention on palifosfamide and the upcoming phase III data, Ziopharm (NASDAQ:ZIOP) released some initial phase I data of Ad-RTS IL-12 in advanced … moreView todays social media effects on ZIOPView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By David SobekPalifosfamide is a bifunctional alkylator developed by Ziopharm Oncology (NASDAQ:ZIOP) for the treatment of a number of cancers. Soft tissue sarcoma (STS) is the most advanced program with … moreView todays social media effects on ZIOPView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – October 19, 2012 NEW YORK, Oct. 19, 2012 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today issued the following statement regarding a blog entry posted by Richard Pearson, Contributor, on … moreView todays social media effects on ZIOPView the latest stocks trending across Twitter. Click to view dashboard […]
